ZYBERNO
Stock Report
Updated Aug 23, 2026

TARGET GROUP INC. (CBDY)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
TARGET GROUP INC. (CBDY) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-52.1%)
Return on Capital (Capital Efficiency):CRITICAL (-22.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

TARGET GROUP INC. (CBDY) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$740.43K

Valuation Multiples (2)

P/S Ratio:0.21x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$15.40M

Price Action & Momentum (3)

Momentum Percentile:5 / 100
% of 52-Week High:40.0%
B. Profitability Assessment

Return Metrics (4)

ROA:-30.2%
Reinvestment Rate:65.8%
Fundamental Growth Rate (g):-15.0%

Margin Analysis (3)

Operating Margin Ttm:-52.1%
Net Margin Ttm:-52.1%
Ebitda Margin:-26.0%

TTM Performance (3)

Gross Margin Ttm:39.2%
Operating Margin Ttm:-52.1%
Net Margin Ttm:-52.1%

Yield Metrics (2)

Earnings Yield:-$241.67
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:10.4%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-10.9%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):22.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.17x
Quick Ratio:0.05x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.23x
Times Interest Earned:-1.23

Capital Structure (4)

Working Capital:-11,232,219.00
Cash And Cash Equivalents:5,914.00
Long Term Debt:$7.33M
Net Debt:$14.66M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $3.50M
Linear Growth: -10.9%
📊 Click to view full CBDY Revenue analysis & methodology →
Cost Of Revenue Ttm:$2.12M

Profitability Breakdown (2)

Gross profit TTM: $1.37M
Linear Growth: 72.6%
📊 Click to view full CBDY Gross Profit analysis & methodology →
-$1.82M

Bottom Line Performance (3)

-$1.82M
Income Before Tax:-$1.82M
Ebitda Ttm:-910,269.00

Operating Expenses (5)

Operating Expenses:2,177,399.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$0.00
Interest Expense:1,106,902.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-26.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$5.68M
Current Assets:$2.37M
Ppe Net:3,028,948.00
Goodwill:250,786.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:14,333,714.00
Current Liabilities:13,602,817.00
Long Term Debt:$7.33M
Short Term Debt:$7.33M

Equity & Capital (3)

Equity:-$8.66M
Retained Earnings:-$33.10M
Common Stock:850,000,000.00

Working Capital Items (3)

Accounts Receivable:522,374.00
Inventory:1,715,945.00
Accounts Payable:3,149,059.00

Special Items (2)

Contract Liabilities:285,540.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$366.09K
Linear Growth: 22.5%
$0.00

Investment Activities (1)

Investing Cash Flow:-$40.06K

Financing Activities (3)

Financing Cash Flow:$240.57K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:911,598.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.00
Eps diluted TTM: -$0.00
Linear Growth: -13.6%
📊 Click to view full CBDY EPS analysis & methodology →
Earnings Per Share Ttm:-$0.00

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:-$0.01
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.58x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:6.69x
Days Sales Outstanding Ttm:54.55

Inventory Management (2)

Inventory Turnover Ttm:1.24x
Days Inventory Outstanding Ttm:294.95

Payables & Cash Cycle (2)

Days Payable Outstanding:541.29
Cash Conversion Cycle:-191.79
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:65.8%
Fundamental Growth Rate (g):-15.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-10.9%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):22.5%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):72.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:CBDY
Company Name:TARGET GROUP INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:617.03M
Shares Outstanding Basic:617.03M
Shares Outstanding Diluted:617.03M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 14:14:34 UTC
Data Timestamp:2026-08-22T17:18:42.577829
Scroll to Top